abstract |
Disclosed is a pharmaceutical formulation of a beta2integrin agonist comprising an effective amount of a beta2integrin agonist and a pharmaceutically acceptable carrier. Disclosed is a method for activating beta2integrin by allowing beta2integrin to interact with a beta2integrin agonist. A method of treating a patient by administering an effective amount of a beta2integrin agonist and activating beta2integrin is disclosed. A method of treating inflammation by administering a beta2integrin agonist to a patient with inflammation to activate beta2integrin and reduce inflammation is disclosed. Methods of treating and/or preventing renal ischemia-reperfusion (I/R) injury, reducing injury to a patient due to stent insertion, performing assays for identifying small molecule modulators of β 2integrin, detecting disease in a patient, and improving the overall health status of a patient are disclosed. |